AVR

2.27%

$9.00 anteris technologies ltd

2:1000000 million chance of getting brain damage from Herpes, page-66

First 66 Last

Share
Profile

Follow
platinumstandard

2,918 Posts.

193

22/06/15

20:39

Post #: 15510544
Share

Originally posted by trythree ↑

The main point I was trying to make to impartial readers was that the market for herpes vaccine is very difficult to predict with any certainty, but that it was definitely less than any figure quoted on these boards by a long mile.

Comments such as more people in USA have herpes than the entire population of Australia are pure example of this.

The broadly agreed knowns go like this; around 50% of people with HSV-2 are unaware that they have it and it has zero impact on their life what so ever.
Of the other 50% a majority will see signs of shedding and will either disappear or they will take a pill, use some cream and the signs will never appear again and be forgotten.
This leaves a very small amount of people who have recurrent signs, use condoms and or other preventative measures and learn to live with it. This would be the target market and you would think most of the people in this category would be interested in taking the vaccine. This is a very small percentage of the numbers bounced around here.

Few other things to address:

Nobody is going to be rolling out Vaccine's for herpes in schools, or going to to the doctors to get an injection 'just in case', there are bigger day to day problems out there for people to preoccupy themselves with, compared to one of the most harmless diseases out there. Plus I'm pretty sure the current clinical trials are looking at therapeutic treatment and not preventative i.e injecting people who already have Herpes.

There is no record of anybody dying from Herpes alone.

The idea of 'big pharmas' around the world crawling over each other to find a vaccine for HSV-2 is just not true. Genecea and Agenus are biotechs equivalent to that of AHZ compared to Nasdaq standards, and far the multi national pharmas of the world.

A HSV-2 vaccine would be most useful to AIDS sufferers who also have Herpes to minimise the risk of progression, and to sufferers of recurrent shedding who are convinced and or embarrassed by the constant reappearance of signs.

Expand

Making it up as we go. Just wasted my time trying to see if there is logic in the post.

AHZ Price at posting: 6.9¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

First 66 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $9.00		Change 0.200(2.27%)		Mkt cap ! $190.2M

Open	High	Low	Value	Volume
$8.90	$9.48	$8.88	$176.7K	19.75K

Buyers (Bids)

No.	Vol.	Price($)
2	590	$8.80

Sellers (Offers)

Price($)	Vol.	No.
$9.40	70	1

View Market Depth

No.	Vol.	Price($)
2	590	8.800
2	2067	8.680
1	260	8.510
1	300	8.500
1	2	8.420

Price($)	Vol.	No.
9.400	70	1
9.430	105	1
9.490	218	1
9.500	250	1
9.850	1000	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

AVR (ASX) Chart

2:1000000 million chance of getting brain damage from Herpes, page-66

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2:1000000 million chance of getting brain damage from Herpes, page-66

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Banshee's historic trenches prove rich in antimony and gold for GDM

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News